AMEX · Biotechnology

MAIA (MAIA) Stock

$1.42 +0.00% AMEX: MAIA Healthcare

Valuation

MetricValue
Price$1.42
Market Cap$86.34M
P/E Ratio-1.84
P/B Ratio24.94
P/S Ratio0.00
EPS (TTM)$-0.70
52-Week High$3.19
52-Week Low$0.87
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-1100.00%
ROA-220.00%
ROCE-800.00%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.00
Current Ratio1.67

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-8.0M$-16.0M$-20.0M$-17.0M$-24.0M
Net Profit$-13.0M$-16.0M$-20.0M$-23.0M$-22.0M
EPS$-1.18$-1.70$-1.49$-1.05$-0.70
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$11.0M$12.0M$8.0M$10.0M$10.0M
Total Liabilities$2.0M$4.0M$7.0M$7.0M$7.0M
Cash$11.0M$11.0M$7.0M$10.0M$8.7B
Borrowings$0$0$0$0$0

Latest News

MAIA Biotechnology Says Ateganosine Shows 90.5% Disease Control Rate in Phase 2 Expansion Trial MT Newswires · Jul 8, 2026 MAIA Biotechnology Reports Strong Initial Efficacy Data in Third-Line Non-Small Cell Lung Cancer from Phase 2 THIO-101 Part C Expansion Trial GlobeNewswire · Jul 8, 2026 MAIA Biotechnology Completes Part C International Enrollment for Phase 2 Ateganosine Trial MT Newswires · Jun 25, 2026 MAIA Biotechnology Completes International Enrollment in Part C of Phase 2 THIO-101 Expansion Trial in Third-Line Non-Small Cell Lung Cancer GlobeNewswire · Jun 25, 2026 MAIA Biotechnology Opens Enrollment for Phase 2 Expansion Trial of Novel Telomere-Targeting Agent at Winship Cancer Institute of Emory University GlobeNewswire · Jun 18, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-4.0M$-12.0M$-13.0M$-16.0M$-19.0M
Investing Cash Flow$0$0$0$0$0
Financing Cash Flow$1.0M$-1.0M$-2.0M$-1.0M$-1.0M
Net Cash Flow$10.0M$0$-4.0M$2.0M$-1.0M
Free Cash Flow$-4.0M$-12.0M$-13.0M$-16.0M$-19.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-40.01%
Quick Ratio5.59
Interest Coverage—
Return 1Y-15.20%
Return 3Y-33.79%
Return 5Y—

Ownership

Insiders Held14.39%
Institutions Held21.63%
Institutions Float Held25.27%
Institutional HolderSharesReport Date
Solas Capital Management, LLC4,297,0042026-03-31
Alyeska Investment Group, L.p.2,500,0002026-03-31
Vanguard Capital Management LLC2,074,0452026-03-31
683 Capital Management LLC1,066,6662026-03-31
Centric Wealth Management796,7232026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ANVS $1.70 +0.59% -1.54 $33.45M 0.00%
BCABBioAtla, Inc. $3.40 +0.89% -0.08 $4.29M 0.00%
CALCCalciMedica, Inc. $0.73 -3.82% -0.57 $11.55M 0.00%
CELUCelularity Inc. $0.75 +0.13% -0.20 $21.74M 0.00%
ELUT $0.86 -5.33% -1.24 $37.88M 0.00%

About MAIA

MAIA is led by CEO Vlad Vitoc, employs 13 people, headquartered in US, publicly traded since 2022.

MAIA stock trades at $1.42 with a market capitalization of $86.34M. The stock is valued at a price-to-earnings (P/E) ratio of -1.84, price-to-book of 24.94, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.87 and $3.19, and currently trades 55.5% below its 52-week high.

On profitability, MAIA generates a return on equity (ROE) of -1100.00%, return on capital employed of -800.00%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides